Adjunctive DobutAmine in sePtic Cardiomyopathy With Tissue Hypoperfusion
Key facts
- Who runs it
- University Hospital, Limoges
- Where
- France17 sites in 1 countryChoose a country to see its sites
- Trial code
- NCT04166331
- EU 2024-517839-50-00
- EudraCT 2019-000286-21
- U1111-1313-1511
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 136 people enrolled
- Started
- 20 Sept 2020
- Ended
- 1 Jul 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Placebos
- Dobutamine
- Record updated
- 21 November 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Age > 18 years hospitalized in ICU
- > Septic shock (Sepsis-3 definition):; Clinically suspected or documented acute infection; Responsible for organ dysfunction(s): change in SOFA ≥ 2 points; With persisting hypotension (systolic and/or mean arterial pressure < 90 / < 65 mmHg) despite adequate fluid resuscitation (≥ 30 mL/kg, unless presence of pulmonary venous congestion); Requiring vasopressor support (Norepinephrine) to maintain steady mean arterial pressure ≥ 65 mmHg; And lactate > 2 mmol/L
- Septic cardiomyopathy: echocardiographically measured LV ejection fraction (EF) ≤ 40% and LV outflow tract velocity-time integral < 14 cm
- Informed consent
Who cannot take part
- Hypersensitivity to Dobutamine, 5% Dextrose, or to the excipients
- Severe ventricular arrhythmia
- Acute coronary syndrome
- Pregnancy or breast feeding
- Ventricular rate > 130 bpm (sinus rhythm or not)
- Obstructive cardiomyopathy with pressure gradient at rest ≥ 50 mmHg unrelated to uncorrected hypovolemia
- Severe aortic stenosis: mean gradient > 40 mmHg, peak aortic jet velocity > 4 m/s, aortic valve area < 1 cm² (aortic valve area index < 0.6 cm²/m²)
- Decision to limit care or moribund status (life expectancy < 24 h)
- Absence of affiliation to Social Security
- Subjects under juridical protection
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Sepsis induces both a systolic and diastolic cardiac dysfunction. The prevalence of this septic cardiomyopathy ranges between 30 and 60% according to the timing of assessment and definition used. Although the prognostic role of septic cardiomyopathy remains debated, sepsis-induced left ventricular (LV) systolic dysfunction may be severe and associated with tissue hypoperfusion, while it appears to fully recover in survivors. Accordingly, optimization of therapeutic management of septic cardiomyopathy may contribute to improve tissue hypoperfusion in increasing oxygen delivery, and to reduce related organ dysfunctions in septic shock patients.
Read full original descriptionShow less
Echocardiography is currently the recommended first-line modality to assess patients with acute circulatory failure.
Current Surviving Sepsis Campaign strongly recommends Norepinephrine as the first-choice vasopressor in fluid-filled patients with septic shock. In contrast, the use of Dobutamine is only suggested (weak recommendation, low quality of evidence) in patients with persistent tissue hypoperfusion despite adequate fluid resuscitation and vasopressor support. Levosimendan, an alternative inodilator, has failed preventing acute organ dysfunction in septic patients and has induced more supraventricular tachyarrhythmias than in the control group. Data supporting Dobutamine in this setting are scarce and primarily physiologic and based on monitored effects of this drug on hemodynamics and indices of tissue perfusion.
No randomized controlled trials have yet compared the effects of Dobutamine versus placebo on clinical outcomes. In open-labelled, small sample trials, the ability of septic patients to increase their oxygen delivery during Dobutamine administration appears to be associated with lower mortality.
The tested hypothesis in the ADAPT trial is that Dobutamine will reduce tissue hypoperfusion and associated organ dysfunctions in patients with septic shock and associated septic cardiomyopathy. In doing so, it may participate in improving clinical outcomes.
The 2 groups in the trial
- ControlPlacebo, for comparison
Placebo will initially be started at a dose of 2.5 µg/kg/min and subsequently titrated using incremental steps (predefined durations) of 2.5 µg/kg/min, up to a maximal dose of 10 µg/kg/min
Treatment: Placebos
- ExperimentalTreatment being tested
Dobutamine will initially be started at a dose of 2.5 µg/kg/min and subsequently titrated using incremental steps (predefined durations) of 2.5 µg/kg/min, up to a maximal dose of 10 µg/kg/min
Treatment: Dobutamine
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Adjunctive DobutAmine in sePtic Cardiomyopathy With Tissue Hypoperfusion: a Randomized Controlled Multi-center Trial
- Publications
- Record updated
- 21 November 2025